Investor Risk Appetite in Biotechnology: Global economic uncertainties and geopolitical conflicts (like the Middle East conflict) can reduce investor appetite for speculative, clinical-stage biotech companies that rely heavily on capital raises for R&D and clinical trials.

Interest Rate Environment and Cost of Capital: A 'higher-for-longer' interest rate environment, potentially influenced by global growth concerns, could increase borrowing costs for Dyne Therapeutics, impacting its ability to fund extensive clinical development without significant cash burn.

Biotech-Specific Regulatory and Clinical Trial Success: As a clinical-stage company, Dyne's stock is highly sensitive to positive or negative developments in its clinical trials and interactions with regulatory bodies like the FDA. Successes in advancing its drug candidates (e.g., z-basivarsen) through trials and towards approval are critical drivers.